Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics

By Yuki Shinohara, AJIPHASE® team member at Aji Bio-Pharma

After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene. Over the next several years, the market is poised to grow significantly, with 16 oligonucleotide drugs approved in Japan in 2022. As interest in these therapies accelerates, manufacturers and researchers are working to develop processes that address the significant environmental burdens of oligonucleotide manufacturing while saving resources and improving scalability.

Waste, chemical hazards, and energy efficiency are all important considerations as manufacturers set out to increase production volumes of therapeutic oligonucleotides. In response to this priority, Aji Bio-Pharma, a leading research, development, and manufacturing organization, has developed two sustainable solutions for oligonucleotide production: AJIPHASE liquid phase synthesis, which reduces the use of raw materials, and the enzymatic method, which simplifies the purification process. Download the full article to learn more about these methodologies and explore innovations that maintain scalability while reducing waste and consumption.